Floatz logo

Cediranib

Recurrent B-Cell Non-Hodgkin Lymphoma

Mayo ClinicSmall moleculePhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Recurrent B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
CARMUSTINE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
Irinotecan
M.D. Anderson Cancer Center
Phase 3BB
Vorinostat
M.D. Anderson Cancer Center
Phase 2B
Recombinant Human Hyaluronidase
Academic and Community Cancer Research United
Phase 2B

View all 24 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →